{"id":6951,"date":"2013-05-29T05:48:17","date_gmt":"2013-05-29T09:48:17","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=6951"},"modified":"2013-05-29T05:48:17","modified_gmt":"2013-05-29T09:48:17","slug":"oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951","title":{"rendered":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#8217;s New Chief Medical Officer"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 05\/29\/2013 (wallstreetpr) &#8211;\u00a0Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) involved in the development of bio technology products for delivering oxygen to tissue had been witnessing decline in the share prices. The shares of the company declined by 12.95 percent to close at $3.90 per share for last trading session. The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had been trading in the range of $3.90 to $4.30 per share during the day.<\/p>\n<p style=\"text-align: justify;\">Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently appointed Dr. Charles L. Pamplin III as the chief medical officer who will further be responsible for strategic clinical development plan of the company. The bio pharmaceutical company is involved in the development of Oxycyte, a systemic perfluorcarbon product.<\/p>\n<p style=\"text-align: justify;\">Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently announced a reverse stock split to its shareholders at the ratio of twenty to one after proper approval from the company\u2019s shareholders and the board of directors on April 26, 2013. The company had till now developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications.<\/p>\n<p style=\"text-align: justify;\">The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recorded 52 week low price level of $3.6 per share and 52 week high price level of $45 per share. The company presently holds 2.66 million shares outstanding and the institutional ownership of 5 percent of the holdings. The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had witnessed heavy trading volume at 33,046 shares for the last trading session while the average trading volume for the company is only 4,094 shares per day.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 05\/29\/2013 (wallstreetpr) &#8211;\u00a0Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) involved in the development of bio technology products for delivering oxygen to tissue had been witnessing decline [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":6952,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2332,2331],"stock_ticker":[],"class_list":["post-6951","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqoxbt","tag-oxygen-biotherapeutics-inc-nasdaqoxbt","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#039;s New Chief Medical Officer - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#039;s New Chief Medical Officer - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 05\/29\/2013 (wallstreetpr) &#8211;\u00a0Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) involved in the development of bio technology products for delivering oxygen to tissue had been witnessing decline [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-05-29T09:48:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#8217;s New Chief Medical Officer\",\"datePublished\":\"2013-05-29T09:48:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg\",\"keywords\":[\"NASDAQ:OXBT\",\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\",\"name\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)'s New Chief Medical Officer - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg\",\"datePublished\":\"2013-05-29T09:48:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#8217;s New Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)'s New Chief Medical Officer - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951","og_locale":"en_US","og_type":"article","og_title":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)'s New Chief Medical Officer - Wall Street PR","og_description":"Boston, MA 05\/29\/2013 (wallstreetpr) &#8211;\u00a0Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) involved in the development of bio technology products for delivering oxygen to tissue had been witnessing decline [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-05-29T09:48:17+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#8217;s New Chief Medical Officer","datePublished":"2013-05-29T09:48:17+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg","keywords":["NASDAQ:OXBT","Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951","url":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951","name":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)'s New Chief Medical Officer - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg","datePublished":"2013-05-29T09:48:17+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/pillsinaflask.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbts-new-chief-medical-officer-6951#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)&#8217;s New Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=6951"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6951\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/6952"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=6951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=6951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=6951"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=6951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}